佐剂
中和抗体
免疫系统
病毒学
抗体
免疫学
接种疫苗
人口
脾细胞
生物
甲型流感病毒
病毒
灭活疫苗
医学
环境卫生
作者
Andreas Wack,Barbara C. Baudner,Anne Katrin Hilbert,Ilaria Manini,Sandra Nuti,Silvia Tavarini,Hanno Scheffczik,Mildred Ugozzoli,Manmohan Singh,Jina Kazzaz,Emanuele Montomoli,Giuseppe Del Giudice,Rino Rappuoli,Derek T. O’Hagan
出处
期刊:Vaccine
[Elsevier]
日期:2008-01-01
卷期号:26 (4): 552-561
被引量:174
标识
DOI:10.1016/j.vaccine.2007.11.054
摘要
Influenza is controlled by protective titres of neutralizing antibodies, induced with the help of CD4 T-cells, and by antiviral T-cell effector function. Adjuvants are essential for the efficient vaccination of a naïve population against avian influenza. We evaluated a range of adjuvants for their ability to enhance, in naïve mice, protective hemagglutination inhibition (HI) titres, which represent the generally accepted correlate of protection, virus-neutralizing titres and T-cell responses to a new generation influenza vaccine produced in cell culture. The selected adjuvants include alum, calcium phosphate (CAP), MF59, the delivery system poly-(lactide co-glycolide) (PLG) and the immune potentiator CpG. MF59 was clearly the most potent single adjuvant and induced significantly enhanced, long-lasting HI and neutralizing titres and T-cell responses in comparison to all alternatives. The combination of alum, MF59, CAP or PLG with CpG generally induced slightly more potent titres. The addition of CpG to MF59 also induced a more potent Th1 cellular immune response, represented by higher IgG2a titres and the induction of a strongly enhanced IFN-gamma response in splenocytes from immunized mice. These observations have significant implications for the development of new and improved flu vaccines against pandemic and inter-pandemic influenza virus strains.
科研通智能强力驱动
Strongly Powered by AbleSci AI